News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2019. “As we pass through mid-2019, we are very pleased to announce strong
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019
CAMBRIDGE, Mass. , July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2019 .
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , June 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Goldman Sachs 40 th Annual Global Healthcare Conference on Tuesday, June 11, 2019 at
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , May 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., May 23, 2019 -- Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, released the following statement on the report from the Institute for Clinical and Economic Review (“ICER”) on treatments for Duchenne muscular dystrophy: Sarepta is committed
View HTML
Toggle Summary Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three months ended March 31, 2019 . “Having built out our multi-platform portfolio of genetic medicine
View HTML
Toggle Summary Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
--Expands pipeline with 6 th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
CAMBRIDGE, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, May 8, 2019 . Subsequently, at 4:30 p.m.
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.